Works in Oncologist, 2025, Vol 30, Issue 6

Results: 55
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.

    Published in:
    Oncologist, 2025, v. 30, n. 6, p. 1, doi. 10.1093/oncolo/oyaf138
    By:
    • Beckermann, Kathryn E;
    • Shah, Neil J;
    • Campbell, Matthew T;
    • Haas, Naomi B;
    • Nelson, Ariel;
    • Ornstein, Moshe C;
    • Mao, Shifeng;
    • Keshava-Prasad, Holavanahalli S;
    • Hammers, Hans;
    • Gao, Xin;
    • Gourdin, Theodore;
    • George, Saby;
    • Hoimes, Christopher J;
    • Hussain, Arif;
    • Jonasch, Eric;
    • Rini, Brian I;
    • Voss, Martin H
    Publication type:
    Article
    25
    26

    REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens.

    Published in:
    Oncologist, 2025, v. 30, n. 6, p. 1, doi. 10.1093/oncolo/oyaf135
    By:
    • Zhong, Jeffrey;
    • Jang, Albert;
    • Abuqayas, Bashar;
    • Basu, Arnab;
    • Benjamin, David J;
    • Bhatlapenumarthi, Vineel;
    • Bilen, Mehmet Asim;
    • Buch, Dhvani;
    • Chang, Mark;
    • Chin, Erica;
    • Darabi, Sourat;
    • Dhanikonda, Nagendra;
    • Ghatalia, Pooja;
    • Grigg, Claud M;
    • Grier, Abby L;
    • Jindal, Tanya;
    • Jung, Joannah;
    • Kilari, Deepak;
    • Kumar, Hamsa L S;
    • Lee, Suzanna
    Publication type:
    Article
    27
    28
    29
    30
    31
    32
    33
    34
    35

    Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study.

    Published in:
    Oncologist, 2025, v. 30, n. 6, p. 1, doi. 10.1093/oncolo/oyaf125
    By:
    • Evrard, Camille;
    • Pelras, Antoine;
    • Rivet, Simon;
    • Bachet, Jean-Baptiste;
    • Dubreuil, Olivier;
    • Pointet, Anne-Laure;
    • Taieb, Julien;
    • Lahlou, Widad;
    • Portal, Alix;
    • Lepère, Céline;
    • Lecomte, Thierry;
    • Chautard, Romain;
    • Williet, Nicolas;
    • Phelip, Jean-Marc;
    • Coutzac, Clélia;
    • Soularue, Emilie;
    • Marthey, Lysiane;
    • Abdallah, Raëf;
    • Bidault, Anne Thirot;
    • Artru, Pascal
    Publication type:
    Article
    36
    37

    Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy.

    Published in:
    Oncologist, 2025, v. 30, n. 6, p. 1, doi. 10.1093/oncolo/oyaf123
    By:
    • Jacobs, Flavia;
    • Gaudio, Mariangela;
    • Andreottola, Chiara;
    • Borroni, Riccardo;
    • Benvenuti, Chiara;
    • Saltalamacchia, Giuseppe;
    • Gerosa, Riccardo;
    • Canzian, Jacopo;
    • Tiberio, Paola;
    • Torrisi, Rosalba;
    • Masci, Giovanna;
    • Miggiano, Chiara;
    • Zambelli, Alberto;
    • Santoro, Armando;
    • Sanctis, Rita De
    Publication type:
    Article
    38

    Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events.

    Published in:
    Oncologist, 2025, v. 30, n. 6, p. 1, doi. 10.1093/oncolo/oyaf120
    By:
    • Mizuno, Kazuyuki;
    • Ito, Takanori;
    • Sawada, Tsunaki;
    • Kobayashi, Tomoko;
    • Iwama, Shintaro;
    • Mori, Shoichiro;
    • Hase, Tetsunari;
    • Fukami, Yuki;
    • Furusawa, Kenji;
    • Yura, Yoshimitsu;
    • Morimoto, Ryota;
    • Sajiki, Ai Fujita;
    • Ushida, Hiroaki;
    • Kato, Noritoshi;
    • Maruyama, Shoichi;
    • Murohara, Toyoaki;
    • Katsuno, Masahisa;
    • Ishii, Makoto;
    • Akiyama, Masashi;
    • Arima, Hiroshi
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50